Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome
Read abstract ›
Opioid substitution treatment is linked to reduced risk of death in opioid use disorder
Deaths related to the “epidemic” of opioid use disorder are inescapable realities in communities across North America, with tags like “the American Carnage” and “this generations’ AIDS crisis” in the lay press. Prescription opioids, heroin, and, more recently, fentanyl have all contributed to a precipitous rise in deaths related to opioid overdose. Read abstract ›
Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies
To compare the risk for all cause and overdose mortality in people with opioid dependence during and after substitution treatment with methadone or buprenorphine and to characterise trends in risk of mortality after initiation and cessation of treatment. Read abstract ›
Predictors of induction onto extended-release naltrexone among unemployed heroin-dependent adults
Extended-release naltrexone (XR-NTX) blocks the effects of opioids for 4 weeks; however, starting treatment can be challenging because it requires 7 to 10 days of abstinence from all opioids. In the present study we identified patient and treatment characteristics that were associated with successful induction onto XR-NTX. Read abstract ›
Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone
Opioid use disorder is often treated with short term hospitalization and medically supervised withdrawal from opioids followed by counseling alone without medication assisted treatment (MAT). More evidence is needed to confirm the expectation that the rate of relapse would be high after short term inpatient treatment and withdrawal from opioids without follow-up MAT. Read abstract […]
Open-label 24-month study of injectable extended-release naltrexone (XR-NTX) in healthcare professionals with opioid dependence
Read abstract ›
Trump Administration awards grants to states to combat opioid crisis
HHS will administer grants totaling $485 million to all 50 states Secretary Price sends letter to governors: “Through a sustained focus on people, patients, and partnerships, I am confident that together we can turn the tide on this public health crisis.” Health and Human Services Secretary Tom Price, M.D. today announced that HHS will soon […]
Harvard to offer free online class on the opioid crisis
Harvard is launching a free online course designed to educate people about the opioid epidemic in the US. Instructors will cover the medical basics, such as how opioids are used to treat pain and how pathways in the brain can play a part in addiction. They’ll also touch on the epidemic’s legal aspects — including […]
Medication-Assisted Treatment for Adolescents in Specialty Treatment for Opioid Use Disorder
Read abstract ›
HCV Treatment Is Effective Among People with Drug Use and/or Receiving Opioid Agonist Treatment
Many insurance payers in the US restrict access to direct-acting antivirals (DAA) for chronic hepatitis C (HCV) infection if patients have illicit substance use or are receiving opioid agonist treatment (OAT). Three phase 3 multi-center trials (the “ION” trials) evaluated the efficacy and safety of ledipasvir/sofosbuvir ± ribavirin in patients with chronic genotype 1 HCV […]
